Ronovo Surgical has announced the closing of its Series D financing round, bringing in $67 million in new capital. The round was led by Johnson & Johnson’s corporate venture arm, JJDC, and included participation from Lilly Asia Ventures, INCE Capital, and Granite Asia.
This marks Ronovo’s second significant funding milestone in 2025, following a Series C round earlier this year, also led by Granite Asia. With over $100 million raised in just a few months, Ronovo is rapidly gaining momentum and investor confidence as it continues to push the boundaries of minimally invasive surgery.
The infusion of capital comes at a pivotal time for the company, which is actively expanding its commercial and clinical footprint. Ronovo’s flagship product, Carina, is a modular robotic surgery platform designed to address long-standing limitations in surgical robotics. Unlike traditional systems, which are often rigid, costly, and challenging to scale, Carina offers a flexible and adaptable architecture that can be configured to meet the specific needs of various surgical specialties and hospital environments. This modularity not only improves accessibility for a broader range of institutions but also allows surgeons to tailor the system to their preferred workflows.
Earlier this year, Carina received regulatory approval from China’s National Medical Products Administration (NMPA), becoming the first modular robotic surgical system in the country to secure a first-time filing across four major specialties: General Surgery, Gynecology, Urology, and Thoracic Surgery. This milestone has positioned Ronovo as a leader in the Chinese surgical robotics market, where demand for advanced yet cost-effective solutions continues to grow.
In connection with the Series D financing, Ronovo has entered into a targeted collaboration agreement with Johnson & Johnson Medical (Shanghai) Ltd. The partnership aims to expand access to advanced surgical technologies in China by offering hospitals the combined benefits of Carina and Johnson & Johnson MedTech’s complementary surgical tools. This collaboration reflects a shared commitment to enhancing surgical outcomes and expanding the accessibility of cutting-edge medical technologies across various healthcare settings.
Beyond China, Ronovo is setting its sights on global expansion. Regulatory submissions are already underway in Europe and South America, and the company is actively engaging with key opinion leaders and clinical partners in these regions. Early feedback from international experts has been overwhelmingly positive, with many highlighting Carina’s unique ability to meet the practical and economic challenges faced by healthcare systems worldwide.
The company’s progress is not just technical—it’s deeply human. At its core, Ronovo is driven by a mission to make high-quality surgical care more accessible and more effective. By rethinking the design and deployment of robotic systems, the company is helping to democratize advanced surgery, making it accessible to more patients in more locations with fewer barriers.
How the funding will be used: With the Series D funding now secured, Ronovo plans to accelerate product development, expand its commercial team, and deepen its clinical partnerships. The company is also investing in ongoing innovation across its pulsed electric field platform, which underpins the Carina system and offers a new approach to surgical intervention that is precise, non-thermal, and tissue-sparing.
KEY QUOTE:
“We are grateful for the successful closing of our Series D round led by JJDC. Carina—flexible, adaptable, and affordable—embodies our commitment to democratizing access to surgical robotics on a global scale. We’re excited about the strategic collaboration with Johnson & Johnson MedTech, which will further accelerate our commercial momentum in China while laying the foundation for international growth.”
Dr. John Ma, Founder, Chairman, and CEO of Ronovo Surgical
